Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings largely remain positive.
Stocks · News reference
Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $25
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $30
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $24 to $30.
B. Riley Securities Reiterates Buy on Climb Bio, Raises Price Target to $30
B. Riley Securities analyst Mayank Mamtani reiterates Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $26 to $30.